Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

ral and administrative costs should show minimal increases for the last quarter of FY07 and throughout FY08.

Importantly, Unigene restructured its loan obligations earlier this year in May 2007 and eliminated its "going concern" status. The loans are primarily from officers and total approximately $16 million. They are now recast over eight years at 9 percent interest with no payments due (interest will accrue) for the first three years and no prepayment penalties.

With Fortical gaining market share, an advancing pipeline targeting large markets, a near-term positive bottom line, and huge upside potential, we believe that Unigene represents a significant opportunity for investors.

Risks

UGNE currently has only one product on the market. Any changes in market demand, USL's ability to market the product, any regulatory changes, or any delays in production would have a significant negative impact on the Company.

UGNE has products in its pipeline in various stages of development; however, Unigene may never develop another product that receives regulatory approval.

Unigene has incurred significant operating losses since its inception. The most recent quarter (September 2007) showed an accumulated deficit of $121.6 million. UGNE is dependent on partnerships and collaborations in the development of its pipeline. The Company's inability to establish new partnerships and to maintain current corporate partnerships and licensing arrangements would negatively impact the progress of the Company.

The pharmaceutical industry is extremely competitive in general, and with the aging population swelling the ranks of osteoporosis sufferers, competition in this market has heated up. Unigene competes with large companies with established products and other therapies that may emerge and displace calcitonin.

Indication: The complete report including tables and pictures can be downloaded free of charge as a pdf-file under

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... the first Wisconsin governor elected to four consecutive terms, and ... governor to be tagged with radio frequency identification for digital ... Thompson, who also served as Secretary of Health and ... of the security technology firm Applied Digital's VeriChip ...
... Madison, Wis. - The Wisconsin Alumni Research Foundation ... Chemicon to commercialize research products using WARF's stem ... Tuesday. , ,Chemicon will have non-exclusive access to WARF's ... patented through the University of Wisconsin-Madison . ...
... Technologies of suburban Madison has received a Phase ... from the National Cancer Institute. The grant is to ... of protein activity, useful for cancer research. , ,Last ... grant for $2.14 million from the National Institute for ...
Cached Biology Technology:Tommy Thompson to get RFID implant 2Tommy Thompson to get RFID implant 3WARF signs stem cell agreement with California firm 2
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of healthcare stakeholders address questions related to health ... disparities in a two-day invitational roundtable on March ... Health Policy, the Agency for Healthcare Research and ... Participants represent the perspectives and concerns of community ...
... Improved environmental conditions have enabled the otter ( Lutra ... years. However, the recovery of populations of this mammal has ... human activities still prevents the species from gaining a foothold. ... acts as a strong impediment to the expansion of the ...
... only a structural support protein in the microenvironment of breast ... However, laminin is far more than just a ... one of the world,s foremost breast cancer scientists have shown ... breast cancer, ,the second most common cancer and second leading ...
Cached Biology News:HIT's impact on health disparities: Will it help or harm? 2Otters on road to recovery in Andalusia 2Berkeley Lab researchers illuminate laminin's role in cancer formation 2Berkeley Lab researchers illuminate laminin's role in cancer formation 3Berkeley Lab researchers illuminate laminin's role in cancer formation 4Berkeley Lab researchers illuminate laminin's role in cancer formation 5
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
karyopherin alpha2 (2G7)...
Biology Products: